May Gainers (MRNA, account up 0.25%)10th trade in May is NASDAQ:MRNA .
Holding period is 22 days (5/1/23 - 5/23/23).
Account is up 0.25%.
Total return in May is 3.83%.
MRNA trade ideas
Profits Over Patients: The Morally Complex Realm of Big PharmaThis strategy dissects the dual nature of big pharmaceutical firms like Johnson & Johnson, Pfizer, Moderna, and Merck & Co viewed through base Fibonacci Extension Clustering. Despite big pharma's significant contributions to healthcare, these firms have benefited from questionable practices, including price manipulation and exploiting addictions . Price manipulation is a notorious strategy where companies arbitrarily hike drug prices, often without any significant improvements in their efficacy.
"Big Pharma" has faced backlash for allegedly contributing to the opioid crisis . By aggressively marketing highly addictive pain medications , they may have exacerbated a public health catastrophe, leading to thousands of deaths annually.
Such practices illuminate the immoral landscape of the pharmaceutical industry. While these firms play a vital role in global healthcare, their business tactics often prioritize profits over patients, demanding a closer scrutiny of this sector's ethics.
1. Johnson & Johnson (JNJ): Around $440 billion
2. Pfizer Inc. (PFE): Around $240 billion
3. Moderna Inc. (MRNA): Around $110 billion
4. Merck & Co., Inc. (MRK): Around $200 billion
TOTAL = 1 Trillion
Good context for short selling ?support zone become resistance zone also context is looking good for short selling
price is below weekly and monthly VWAP
m30 chart show bearish engulfing to confirm entry
so this level is OK to short
MRNA Short with resistance at 145.50I plan a short trade ( NASDAQ:MRNA ) at 144.41. The entry is just before the resistance zone at ~145.50 which is also confirmed by the Fibonacci 0.5 level. At 146.69 is the stop loss placed so that there is enough space to breathe. The take profit is very conservatively placed at a risk-reward ratio of 1:1.
MRNA ? Buy Weakness MRNA descended this past winter off a head-and-shoulders pattern on the daily chart just under
the demand zone as shown by the LuxAlgo indicator. Price is now in a downtrend heading into
earnings tomorrow. MRNA needs to show something good otherwise it will break through the
demand zone and keep going down.
This is a risky earnings play betting that something will show up on the report to buoy up the
company and its stock. I will risk 0.01% of the trading account on a call option with DTE 5/19/23
looking for a minor surge and so a good quick profit.
( see also the link below)
MRNA finish corrective yet?MRNA m30 show diagonal corrective pattern
divergence and gap down on pre-market
Moderna Very Bearish (Pt 2)Part 1:
The136.50 target was hit and Moderna is now resting at a critical neckline area which bulls have defended for quite some time. I expect a small bounce here but ultimately, a break of this level and a spill much lower. View of the weekly chart below:
This is a head and shoulders within a head & shoulders playing out. It would be invalidated if MRNA can retake the 20 weekly moving average (165.32) and flip it to support.
Bearish price target: 73USD!
Moderna to 136.50I will be looking for a short tomorrow on any bounce.
Bearish marubozo daily candle with a rejection of the 200DMA, cutting through the 50DMA(green) then 20DMA(yellow) like butter and on monster volume. Not good! High probability of downside continuation tomorrow & the 20 + 50 DMAs will now flip from support to resistance.
Downside price target: Major area of support/confluence at 136.50.
While this is in my opinion the most probable scenario, let's scenario cast a few others:
Potential bullish scenarios (neither which is likely to me!)
1.) A gap-up tomorrow then tight trading range day creating a bullish harami.
2.) Further initial continuation tomorrow followed by bulls pushing back hard creating either a hammer or pinbar daily candle signaling a potential bounce to the 2 major moving average resistances.
MRNA Bullish reversal might be MRNA has been in a bearish trend from quite a while but now it has started to move back up
Its following a very good resistance trend retest . The recent drop was due to bad news but it should be back on track soon
According to FIB after crossing 176 the bullish reversal will be confirmed
Entry @ 176
SL 170
TP after 202+
MRNA is going to dump now / where to buyMRNA is not looking too good.
What we can see is a weekly bearish engulfing candle after clear rejection from the upsloping resistance line. Rejection was nasty therefore we're seeing instant follow through.
You can short it now with a final target at the support which is the entry for longs too.
At the support, flip bullish and take a long position. The target is at the key resistance shown on the chart.
If you short now, pleace a stop loss at 219 - 220 $
Good luck
$MRNA: Time at Mode Trend signal fired$MRNA has bottomed recently, and has been trending logically in the daily timeframe, we have a 2nd signal forming here, continuing the uptrend that kicked off on March 13th.
Upside can be substantial given broad market action, so I suggest to get involved with the stock (and likely also $PFE soon) here.
Best of luck!
Cheers,
Ivan Labrie.
Weekly Chart on MRNAThe price is moving into a range which was already tested in 2021.
Possible positive price action on the go on this last wave. But it may be too early to say it.
3/29 Watchlist + NotesSPY - I had no real bias going into today's session other than mentioning last night that downside was more likely to come today because of the failed 2U daily created on monday. We closed slightly red after seeing a decent drop to the high 393 area, forming a weak bearish 2D. Going into wednesday (3/29), I am hoping to see some downward continuation to the 392/390 levels tomorrow to test that range. Key word is hoping. I remain neutral with my personal bias as we have no real clear direction this week still. Given that we closed very weak to the downside leads me to believe we can ultimately go either way tomorrow, but once again, playing what is in front of us I have to be looking more so to the downside.
Watchlist + Bias:
DIS - 2-1 Daily: Slightly Bullish
MRNA - 2-1 Daily: Bearish.
PEP - 2-1 Daily: Bearish
FDX - 3-1- Weekly: Neutral
Main Watch:
MRNA - Back in our main spotlight for the 2nd time this week is MRNA. There is a 2-1 daily setup that is within a bearish week with a lot of room to the downside due to a huge FVG on the daily. Looking to target Monday's low of 145.36 and the 50% retrace point of the original FVG at 144.72. Will only play downside and not upside if markets pump tomorrow
Also heavily watching FDX still as the 3-1 weekly has not broken out yet. Hourly chart stuck in a flat channel currently just consolidating.
Yesterdays Main Watch:
NVDA - (Status:) Winner (Personally Enter?) No
I mentioned we had downside targets and that I wanted to play with markets momentum. I missed entry due to being in class and not being able to trade, but I saw how it played out. Broke short entry level in the first few minutes of market open and dumped past our 260 target to the mid 258 level. Cons ran a little over 75% from entry and realistically I would have caught the full move due to the dump being so consistent and strong before reversing.
Watchlist Stats For The Week:
2/2 On Spy Predictions
2/2 On Main Watch Plays
Top Winner: NVDA (75%+)
Personal Stats:
3/5 for the week.
Overall Green/Red? Green
iS it lookin 2 ht two50?There is a high probability that it can hit 250 in next 3 months, it must break above 170 first. Some big news around 170 can make it hit 250.
3/22 Watchlist + NotesSPY - Once again we were bullish going into today and ended up getting that upside movement we wanted. Tomorrow is FOMC so no real prediction for tomorrows movement other than some chop leading up to the news. As far as the news goes, I am leaning more on the bullish side but quite honestly that is purely a guess. Trading light tomorrow if I take anything, and not trading after news comes out.
Watchlist:
MRNA - 3-1: Bullish
BIDU - 2-1: Neutral
Main Watch:
MRNA - Nothing special about this setup other than it being a 3-1 daily setup and seeing that it has more room to the upside to test a daily FVG around 157.70
Top winner from yesterdays watchlist:
GOOG - 2-1 daily broke to the upside and had a gorgeous uptrend day. Calls ran just under 240% from where the long entry (yesterdays high) was
MRNA to $167After the MacD turned bullish for Moderna, I believe we will finish the harmonic pattern until we hit the trend line at around 167-170.
Not financial advice, good luck to all :)
MRNAXLV did outperform today and so did most health related stocks.
I think this is a beginning of a reversal for the health care sector.
MRNA closed with some bullish volume and a double bottom that will push it to 172 gap close.
Has some downtrend resistance at around 155 but I think it will cut through it.
Bounced off its weekly 200.
$MRNA Watching 786 fib Nice cypher on MRNA, Do not care for the name but it can work.. I will post if get long
MRNA // 134.94 118.55 our support pointsWe need to hold on at 134.94. Our second support point is at 118.55. Those who want to buy from resistance should look for a wedge close in the daily timeframe . Pay attention to the wedge resistance in the weekly timeframe .
$MRNA What Up$MRNA started playing this since it was in the low $20s and then got rid of it at the start of this year. And IMO this is headed under $100. It will get a kick start when the next Pandemic happens and WHO rules lockdowns across the world. Regardless of the hype, I don't see any reason to take a position in this ticker. The only outcome is, EXIT for me :) Although it does have a promising technology but it will not be able to generate the kind of revenue it did with the Pandemic vax
MRNA | This is a BUY | BOUNCEModerna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
$MRNA with a bearish outlook following its earnings #StocksThe PEAD projected a bearish outlook for $MRNA after a negative under reaction following its earnings release placing the stock in drift D .
